Innovative Drug Testing: Araceli Raises $4.5M to Reduce Animal Testing
Innovative Drug Testing: Araceli Raises $4.5M to Reduce Animal Testing
In a groundbreaking development for the biotech industry, Araceli Biosciences has just secured $4.5 million in funding to revolutionize the way we approach drug testing. This Portland-area startup is on a mission to replace traditional animal testing methods with advanced technologies that utilize human cells. Imagine a world where we can develop and test drugs without the need for animal subjects—this is precisely what Araceli aims to achieve!
The company, founded in 2023 as a spinoff from Phoseon Technology, specializes in creating powerful instruments and software designed to capture detailed images of cells while automating the analysis process. Their innovative approach falls under the umbrella of “New Approach Methodologies” (NAMs), which includes human-tissue models and AI-driven simulations. These methods are not just a trend; they’re a necessary evolution in how we conduct preclinical research.
Supporters of NAMs argue that using human cells can lead to more accurate and relevant results compared to animal testing. After all, animals and humans don’t always respond in the same way to drugs, which can result in costly failures during later stages of drug development. Moreover, these alternatives are viewed as a more humane approach to science, aligning perfectly with growing public concerns about animal welfare.
The recent funding round was led by William Cortelyou and included notable investors like Jeff Swickard, a businessman and advocate for animal welfare. With a total of $22.7 million raised so far, Araceli is gaining traction among key players in the pharmaceutical industry. Already, institutions like the Max Planck Institute and Ginkgo Bioworks are utilizing Araceli's innovative technologies, showcasing the potential for wider adoption.
As the National Institutes of Health (NIH) recently announced an $84 million investment into NAMs research, the future looks promising for companies like Araceli. This funding reflects a growing recognition that more humane and effective science is essential. With their cutting-edge technology, Araceli is not just looking to change the landscape of drug testing; they are setting a new standard for what it means to conduct responsible and innovative research. The world of biotech is certainly watching, and we can’t wait to see what comes next!







💬 Comments
Log in to join the conversation.
No comments yet.